The North Carolina Biotechnology Center

The North Carolina Biotechnology CenterCatalyzing economic development and job creation across the stateWhen scientists conducted the first successful genetic-engineering experiments in the 1970s, leaders in North Carolina paid attention. They realized that this emerging technology could bring substantial economic and societal benefits. North Carolina seemed particularly well suited for biotechnology because its traditional industries - especially agriculture, food, forestry, and medicine - were

Written byThe Scientist
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

When scientists conducted the first successful genetic-engineering experiments in the 1970s, leaders in North Carolina paid attention. They realized that this emerging technology could bring substantial economic and societal benefits.

North Carolina seemed particularly well suited for biotechnology because its traditional industries - especially agriculture, food, forestry, and medicine - were among those that could benefit the most. North Carolina also had the necessary resources to develop biotechnology, including world-class research universities, an extensive community college system, abundant natural resources, a highly trained work force, and progressive state leadership.

The only question was: How could North Carolina best pursue biotechnology? A legislative study commission concluded that the state needed an organization dedicated exclusively to biotechnology development. With that imperative, the North Carolina Biotechnology Center was born in 1981 as the world's first government-sponsored biotechnology initiative. Initially a small agency within the Commerce Department, the Center was reconstituted in 1984 as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies